Cancer sales boost Russia's Pharmstandard by 84%

Leading Russian drugmaker Pharmstandard saw third quarter sales leap by 84% to 14.7 billion roubles ($469.3 million), thanks to a new government purchases of cancer drugs. Johnson & Johnson's ($JNJ) Velcade accounted for one-third of that revenue, at 4.8 billion roubles, or $153 million. Report